Antiplatelet Therapy in Patients With Diabetes Mellitus and Acute Coronary Syndrome : New Insights from Randomized Trials

DOI Web Site Web Site PubMed 被引用文献2件 参考文献84件
  • Patti Giuseppe
    Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome
  • Proscia Claudio
    Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome
  • Di Sciascio Germano
    Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome

書誌事項

タイトル別名
  • Antiplatelet Therapy in Patients With Diabetes Mellitus and Acute Coronary Syndrome
  • – New Insights from Randomized Trials –

この論文をさがす

抄録

Patients with diabetes mellitus have increased atherothrombotic risk and elevated rates of recurrent cardiac events, which may be in part attributable to abnormalities of platelet function resulting in increased platelet reactivity. Despite improved clinical outcomes with an antiplatelet strategy of aspirin plus clopidogrel in patients with acute coronary syndrome (ACS), diabetic patients continue to experience relatively high rates of adverse events during follow-up. Thus, strategies using more potent antiplatelet drugs are warranted in diabetic patients with ACS, especially in the presence of an increased coronary angiographic risk profile. The relative benefit of prasugrel has been described as higher in diabetic vs. nondiabetic patients, without increase in the bleeding risk, whereas a reduction in ischemic events was similar with ticagrelor in patients with and without diabetes. Glycoprotein IIb/IIIa inhibitors are indicated in high-risk patients with ACS, but diabetic patients do not benefit from routine administration of such agents.  (Circ J 2014; 78: 33–41)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 78 (1), 33-41, 2014

    一般社団法人 日本循環器学会

被引用文献 (2)*注記

もっと見る

参考文献 (84)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ